Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. GlaxoSmithKline (GSK) is embarking on a ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: GlaxoSmithKline (GSK) and ...

Roche (RHHBY) announced that it will acquire clinical-stage biopharmaceutical company 89bio, Inc. (ETNB) for $3.5 billion in a bid to augment its portfolio in cardiovascular, renal, and metabolic ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal. The transaction includes an upfront ...

GSK plc (LSE/Nueva York:LON:GSK) anunció el lunes la finalización de su adquisición de efimosfermin alfa de Boston Pharmaceuticals. El acuerdo incluye un pago inicial de 1.200 millones de dólares y ...

Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029.” GSK indicated that the addition of efimosfermin expands its pipeline for ...

Efimosfermin is designed to regulate key metabolic pathways to decrease liver fat, reduce liver inflammation, and reverse liver fibrosis in patients with MASH. The drug is currently in trials for ...

GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) GSK plc (LSE/NYSE: GSK) today announced the ...

Treatment-emergent adverse events with efimosfermin alfa were mostly mild to moderate and resolved spontaneously in patients with phenotypic MASH. Among patients receiving efimosfermin, 89% had at ...